PD-L1低表达晚期非小细胞肺癌患者药物治疗进展  

Progression of the related anti-tumor drugs in non-small cell lung cancer patients with negative PD-L1 expression

作　　者：刘颖[1] 周国仁[1] LIU Ying;ZHOU Guoren(The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing,Jiangsu 210009,China)

机构地区：[1]南京医科大学附属肿瘤医院、江苏省肿瘤医院、江苏省肿瘤防治研究所,江苏南京210009

出　　处：《中国临床研究》2023年第6期801-804,共4页Chinese Journal of Clinical Research

基　　金：国家自然科学基金面上项目(82273162)。

摘　　要：随着免疫治疗的不断发展,晚期非小细胞肺癌患者的诊疗也逐渐精准和完善。免疫检查点抑制剂在程序性死亡配体1(PD-L1)高表达的非小细胞肺癌患者中的临床获益明显,但在低表达的患者中的效果仍不确切。本文针对PD-L1低表达的晚期非小细胞肺癌患者可选择的治疗方案进行综述,旨在为该人群的治疗提供参考和选择。With the continuous development of immunotherapy,the treatment of patients with advanced non-small cell lung cancer(NSCLC)is gradually becoming more and more precise.The clinical benefit of immune checkpoint inhibitors in patients with NSCLC with positive programmed cell death-ligand 1(PD-L1)expression is obvious,but the effect in patients with negative expression remains inexact.This article reviews the treatment options available for advanced NSCLC patients with negative PD-L1 expression,aiming at providing references and options for their treatment.

关 键 词：程序性死亡配体1 非小细胞肺癌 晚期 免疫检查点抑制剂 帕博利珠单抗 阿替利珠单抗 卡瑞利珠单抗 纳武利尤单抗 伊匹木单抗 贝伐珠单抗 

分 类 号：R734.2[医药卫生—肿瘤]